Skip to Main Content
Our Commitment to Diversity

K&L Gates Triage: Recent Developments in the 340B Drug Pricing Program

Share via LinkedIn
Share via Twitter
Share via Facebook
Date: 23 July 2020
Triage
By: Andrew D. Ruskin, Victoria K. Hamscho

In this episode, Richard Church, Andrew Ruskin, and Victoria Hamscho discuss recent developments in the 340B Drug Pricing Program, including recent actions by drug manufacturers to limit contract pharmacy access to 340B pricing and impose new reporting requirements on 340B covered entities, as well as a new legislative proposal that would temporarily waive 340B hospital eligibility requirements.

Andrew D. Ruskin
Andrew D. Ruskin
Washington DC
Victoria K. Hamscho
Victoria K. Hamscho
Washington DC
Find more items tagged as: 340B Program and Pharmacy, Health Care and FDA, Health Care Sector, Policy and Regulatory
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel